American Society of Hematology 2023 Annual Meeting
Daniel Wolff, MD, chair of the GVHD Center of the University Hospital in Regensburg, Germany speaks with Aaron Gerds, MD, Editor-in-Chief of ASH Clinical News, about his study, "Safety and Efficacy of Axatilimab at 3 Different Doses in Patients with Chronic Graft-Versus-Host Disease."
Craig A. Portell, MD, of the University of Virginia in Charlottesville speaks with Aaron Gerds, MD, Editor-in-Chief of ASH Clinical News, about his study, "Primary Analysis and Results of Bendamustine, Rituximab, and Venetoclax (BR-VEN) for Initial Treatment of Mantle Cell Lymphoma in Subjects over 60 Years of Age."
Steven Pipe, MD, of the University of Michigan at Ann Arbor speaks with Aaron Gerds, MD, Editor-in-Chief of ASH Clinical News, about his study, "Emicizumab Prophylaxis in Infants with Severe Hemophilia A without Factor VIII Inhibitors: Results from the Primary Analysis of the HAVEN 7 Study."
Raajit K. Rampal, MD, PhD, of Memorial Sloan Kettering Cancer Center in New York City and Naveen Pemmaraju, MD, of the University of Texas MD Anderson Cancer Center in Houston speak with Aaron Gerds, MD, Editor-in-Chief of ASH Clinical News, about their studies, "Pelabresib in Combination with Ruxolitinib for Janus Kinase Inhibitor Treatment-Naïve Patients with Myelofibrosis: Results of the MANIFEST-2 Randomized, Double-Blind, Phase 3 Study" and "Transform-1: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, International Phase 3 Study of Navitoclax in Combination with Ruxolitinib Versus Ruxolitinib Plus Placebo in Patients with Untreated Myelofibrosis."
American Society of Hematology 2022 Annual Meeting
Krina Patel, MD, and fellow Christen Dillard, MD, of University of Texas MD Anderson Cancer Center speak with Aaron Gerds, MD, Editor-in-Chief of ASH Clinical News, about their study, "Racial and ethnic differences in clinical outcomes among multiple myeloma patients treated with CAR T therapy."
Christophe Willekens, MD, of Université Paris-Saclay in Villejuif, France, speaks with Aaron Gerds, MD, Editor-in-Chief of ASH Clinical News, about his study, "Reduced venetoclax exposition to seven days of azacitidine is efficient in treatment-naïve patients with acute myeloid leukemia."
Martin Dreyling, MD, of LMU University Hospital Munich in Germany, speaks with Aaron Gerds, MD, Editor-in-Chief of ASH Clinical News, about his study, "Efficacy and safety of ibrutinib combined with standard first-line treatment or as substitute for autologous stem cell transplantation in younger patients with mantle cell lymphoma: results from the randomized triangle trial by the European MCL Network."
Margaret V. Ragni, MD, MPH, of University of Pittsburgh and Hemophilia Center of Western Pennsylvania, speaks with Aaron Gerds, MD, Editor-in-Chief of ASH Clinical News, about her study, "Multicenter, randomized crossover trial comparing recombinant von Willebrand factor and tranexamic acid for heavy menstrual bleeding in von Willebrand disease."
American Society of Clinical Oncology 2022 Annual Meeting
Aaron Gerds, MD, Editor-in-Chief of ASH Clinical News, and Alexander M. Lesokhin, MD, of Memorial Sloan Kettering Cancer Center discuss Dr. Lesokhin's presentation, "Initial safety results for MagnetisMM-3: A phase 2 trial of elranatamab, a B-cell maturation antigen (BCMA)-CD3 bispecific antibody, in patients (pts) with relapsed/refractory (R/R) multiple myeloma (MM)."
Aaron Gerds, MD, Editor-in-Chief of ASH Clinical News, and Ruben A. Mesa, MD, of UT Health San Antonio, discuss Dr. Mesa's presentation, "MOMENTUM: Phase 3 randomized study of momelotinib (MMB) versus danazol (DAN) in symptomatic and anemic myelofibrosis (MF) patients previously treated with a JAK inhibitor."
Aaron Gerds, MD, Editor-in-Chief of ASH Clinical News, and Paul G. Richardson, MD, of Dana-Farber Cancer Institute in Boston, discuss Dr. Richardson's presentation, "Lenalidomide, bortezomib, and dexamethasone (RVd) ± autologous stem cell transplantation (ASCT) and R maintenance to progression for newly diagnosed multiple myeloma (NDMM): The phase 3 DETERMINATION trial."
